Li Kang Biomedical Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 6/6
Li Kang Biomedical has a total shareholder equity of NT$811.2M and total debt of NT$70.0M, which brings its debt-to-equity ratio to 8.6%. Its total assets and total liabilities are NT$1.1B and NT$295.2M respectively. Li Kang Biomedical's EBIT is NT$99.8M making its interest coverage ratio -29.4. It has cash and short-term investments of NT$566.0M.
Anahtar bilgiler
8.6%
Borç/özkaynak oranı
NT$70.00m
Borç
| Faiz karşılama oranı | -29.4x |
| Nakit | NT$565.96m |
| Eşitlik | NT$811.16m |
| Toplam yükümlülükler | NT$295.22m |
| Toplam varlıklar | NT$1.11b |
Son finansal sağlık güncellemeleri
Recent updates
Li Kang Biomedical (GTSM:6242) Has Some Way To Go To Become A Multi-Bagger
Apr 19
Is Li Kang Biomedical Co., Ltd. (GTSM:6242) A Smart Choice For Dividend Investors?
Mar 09Li Kang Biomedical Co., Ltd.'s (GTSM:6242) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Feb 09The Trends At Li Kang Biomedical (GTSM:6242) That You Should Know About
Jan 19We Think Li Kang Biomedical (GTSM:6242) Can Stay On Top Of Its Debt
Dec 29Three Things You Should Check Before Buying Li Kang Biomedical Co., Ltd. (GTSM:6242) For Its Dividend
Dec 08Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: 6242's short term assets (NT$633.7M) exceed its short term liabilities (NT$177.9M).
Uzun Vadeli Yükümlülükler: 6242's short term assets (NT$633.7M) exceed its long term liabilities (NT$117.3M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: 6242 has more cash than its total debt.
Borcun Azaltılması: 6242's debt to equity ratio has reduced from 12% to 8.6% over the past 5 years.
Borç Kapsamı: 6242's debt is well covered by operating cash flow (104.5%).
Faiz Kapsamı: 6242 earns more interest than it pays, so coverage of interest payments is not a concern.